Artivion Completes Acquisition of Endospan for $175M
Endospan announced that Artivion has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration PMA approval of the NEXUS Aortic Arch System. The purchase price for the acquisition is $175M less offsets for previously provided loans, plus a potential for up to $200M in additional consideration contingent upon U.S. NEXUS commercial performance over the next two years. "The FDA approval of the NEXUS system was a pivotal moment for aortic surgeons seeking a technology specifically designed to treat the ascending and aortic arch," said Kevin Mayberry, Chief Executive Officer at Endospan. "With Artivion's acquisition of Endospan, this differentiated technology is being positioned within a company that understands the aortic space through a differentiated portfolio serving the multidisciplinary approach of open, endo and hybrid solutions."
